medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2009, Number 2

<< Back Next >>

Ann Hepatol 2009; 8 (2)

The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation

Cadden ISH, Greanya ED, Erb SR, Scudamore CH, Yoshida EM

Language: English
References: 34
Page: 158-161
PDF size: 39.83 Kb.


Text Extraction

Portopulmonary hypertension (PPH) is an infrequent, but well-recognized complication of liver cirrhosis. PPH in those with end-stage liver disease has a significant impact on per-operative and intra-operative mortality, with liver transplantation being contraindicated in those individuals with mean pulmonary artery pressure exceeding 50 mmHg. Vasodilatory therapy is the mainstay of pharmacotherapy for PPH, although the evidence of benefit is largely extrapolated from the pulmonary hypertension literature. We report the use of the phosphodiesterase inhibitor, sildenafil, in a patient with end stage liver disease and PPH, with a pulmonary artery pressure before transplantation of 75 mmHg, to reduce pulmonary artery pressure prior to a successful liver transplant.


REFERENCES

  1. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-44.

  2. Strange JW, Wharton J, Phillips PG, Wilkins MR. Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci 2002; 102: 253-68.

  3. Lebrec D, Capron JP, Dhumeaux D, Benhamou JP. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 1979; 120: 849-56.

  4. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127: 437-41.

  5. Hadengue A, Benhayou MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-8.

  6. Yang YY, Lin HC, Lee WC, Hou MC, Lee FY, Chang FY, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001; 36: 181-6.

  7. Michael AE, Ramsay B, Simpson R, Nguyen AT, Ramsay KG, East C, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transplant Surg 1997; 3: 494-500.

  8. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-450.

  9. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, et al. Frequency and clinical implications of increased pulmonary pressure in liver transplant patients. Mayo Clin Proc 1996; 71: 543-51.

  10. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, et al. Pulmonary vascular disorder in portal hypertension. Eur Respir J 1998; 11: 1153-66.

  11. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-8.

  12. Halank M, Ewert R, Seyfarth HJ, Hoeffken G. Portopulmonary hypertension. J Gastroenterol 2006; 41: 837-847.

  13. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA et al. Screening, early detection and diagnosis of pulmonary arterial hypertension. Chest 2004; 126: 14S-34S.

  14. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation : a prospective study. Hepatology 2003; 37: 401-9.

  15. Csete M. Intraoperative management of liver transplant patients with pulmonary hypertension. Liver Transpl Surg 1997; 3: 454-455.

  16. Mandell MS, Krowka MJ. Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease. Anesthesiology 1997; 87: 450-451.

  17. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KT, East C, Klintman GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3: 494-500.

  18. Mandell MS, Groves BM. Pulmonary hypertension in liver disease. Clin Chest Med 1996; 17: 17-33.

  19. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. New Engl J Med 1992; 327: 76-81.

  20. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65: 457-9.

  21. Krowka MJ, Mandell MS, Ramsay MAE, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transp 2004; 10: 174-82.

  22. Wang YW, Lin HC, Yang YY, Hou MC, Lee SD. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. J Gastroenterol 2006; 41: 593-597.

  23. Schroeder RA, Rafii AA, Plotkin JS, Johnson LB, Rustgi VK, Kuo PC. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. Transplantation 2000; 70: 548-50.

  24. Halank M, Marx C, Miehlke S, Hoeffken G. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 2004; 39: 1222-3.

  25. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J et al. Bosentan therapy for portopulmonary hypertension. Eur Resp J 2005; 25: 502-8.

  26. Halank M, Miehlke S, Hoffken G, Schmeisser A, Schulze M, Strasser RH. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77: 1775-6.

  27. Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel W. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2: 1039-42.

  28. Rubin LJ, Badesch DB, Barst R, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.

  29. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for the portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transplantation 2004; 10: 945-950.

  30. Chua R, Keogh A, Miyashita M. Novel use of Sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005; 24: 498-500.

  31. Callejas-Rubio JL, Salmeron-Escobar J, Gonzalez-Calvin J, Ortego-Centeno N. Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil. Liver Transpl 2006; 12: 690-1.

  32. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H et al. Sildenafil treatment for portopulmonary hypertension. Eur Resp J 2006; 28: 563-7.

  33. Colle I, De Vriese AS, Van Vlierberghe H, Lameire NH, De Vos M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int 2004; 24: 63-8.

  34. Charalabos T, Ageliki C, Spiros D. Sildenafil (Viagra) is a risk factor for acute variceal bleeding. Am J Gastroenterol 2002; 97: 1856.




2020     |     www.medigraphic.com